Spinal Muscular Atrophy Treatment Market Players:
- American Physical Therapy Association
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Astellas Pharma
- Beijing Jinlan Gene Technology Co., Ltd.
- Biogen Inc.
- Boston's Children Hospital
- Children's Hospital of The King's Daughters
- F. Hoffmann-La Roche Ltd.
- Hanugen Therapeutics
- Nationwide Children’s Hospital
- NMD Pharma A/S
- Novartis AG
- Pfizer, Inc.
- Scholar Rock, Inc.
Companies in the spinal muscular atrophy treatment market are focusing on offering more effective long-term solutions. Many are investing in personalized medicines, targeting specific genetic mutations, while others are enhancing patient access through pricing strategies, reimbursement partnerships, and early screening programs. In October 2024, Roche presented two-year positive data from the ongoing study RAINBOWFISH at the 29th World Muscle Society assessing the efficacy and safety of risdiplam in children with SMA. Gaining regulatory approvals, and entering new markets are also a key strategy adopted by the prominent players.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of spinal muscular atrophy treatment is estimated at USD 5.94 billion.
The global spinal muscular atrophy treatment market size crossed USD 5.13 billion in 2025 and is likely to register a CAGR of over 17.5%, exceeding USD 25.73 billion revenue by 2035.
North America spinal muscular atrophy treatment market will dominate over 48.90% share by 2035, driven by the presence of leading biotechnology firms at the forefront of developing novel therapies, a robust healthcare infrastructure, and strong government support in North America.
Key players in the market include PTC Therapeutics, Voyager Therapeutics, Inc, Astellas Pharma Inc., Novartis AG, Pfizer, Inc., F. Hoffmann-La Roche Ltd, CYTOKINETICS, INC., Ionis Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc.
